EB103

About Estrella Immunopharma

Estrella Immunopharma's mission is to extend the curative power of T-cell therapies to a broader range of cancers and autoimmune diseases by addressing the critical limitations of current CAR-T products. The company has achieved an 83% overall response rate in a proof-of-concept study for B-cell lymphoma with its lead ARTEMIS candidate, EB103, and reported no severe CRS. Its strategy involves first advancing its CD19-targeted programs in hematologic malignancies, then leveraging a unique oncolytic virus-based 'mark-and-kill' platform to tackle the vast solid tumor market, while also exploring applications in autoimmune conditions like lupus.

Therapeutic Areas

Other Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NHL) Drugs